RT Generic
T1 PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis
A1 Garcia Campelo, Maria Rosario
A1 Arriola, Edurne
A1 Campos Balea, Begona
A1 Lopez-Brea, Marta
A1 Fuentes-Pradera, Jose
A1 de Castro Carpeno, Javier
A1 Aguado, Carlos
A1 Perez Parente, Diego
A1 de Oro Pulido, Fidel
A1 Ruiz-Gracia, Pedro
A1 Rodriguez-Abreu, Delvys
K1 non-small cell lung cancer
K1 network meta-analysis
K1 immunotherapy
K1 first-line treatment
K1 PD-L1 inhibitors
K1 safety
K1 Pd-1/pd-l1 inhibitors
K1 Open-label
K1 Chemotherapy
K1 Pembrolizumab
K1 Efficacy
K1 Therapy
K1 Tolerability
K1 Multicenter
K1 Expression
K1 Nivolumab
AB This network meta-analysis (NMA) evaluates the safety of first-line programmed death-ligand 1 (PD-L1) inhibitor monotherapy in advanced NSCLC patients compared to platinum-based chemotherapy. We also compared the risk of adverse events (AEs) according to programmed cell death-1 receptor (PD-1) or PD-L1 inhibitors therapy. To that end, we conducted a series of metanalyses (MAs) using data from six phase III clinical trials, including 4053 patients. Our results show a reduced risk of any grade treatment-related AEs (risk ratio (RR) = 0.722 95% CI: 0.667-0.783, p = 0.002), and grade 3-5 AEs (RR = 0.406 95% CI: 0.340-0.485, p = 0.023) in immunotherapy as compared to chemotherapy. In contrast, a higher risk of immune-related AEs (irAEs) was estimated for immunotherapy versus chemotherapy. The subgroup MAs comparing PD-L1 to PD-1 inhibitors, determined a lower risk of AEs leading to treatment discontinuation in the anti-PD-L1 subgroup (RR = 0.47 95% CI: 0.29-0.75, p = 0.001); however, this statistically significant difference between anti-PD-L1 and anti-PD-1 subgroups was not reached for other safety outcomes analyzed. In conclusion, our findings show that PD-L1 inhibitor monotherapy improves safety outcomes in the 1L treatment of advanced NSCLC patients as compared to chemotherapy except for irAEs.
PB Mdpi
YR 2021
FD 2021-10-01
LK https://hdl.handle.net/10668/27155
UL https://hdl.handle.net/10668/27155
LA en
DS RISalud
RD Apr 11, 2025